Completed
Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France
What is being collected
Data Collection
Collected from today forward - ProspectiveWho is being recruted
Mental Disorders
+ Schizophrenia Spectrum and Other Psychotic Disorders
+ Schizophrenia
From 18 to 130 Years
+6 Eligibility Criteria
How is the trial designed
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Observational
Study Start: December 2012
Summary
Principal SponsorAstraZeneca
Last updated: December 15, 2015
Sourced from a government-validated database.Claim as a partner
Study start date: December 1, 2012
Actual date on which the first participant was enrolled.Description of the use of Quetiapine Extended Release (XR) in real-life practice in France
Principal SponsorAstraZeneca
Last updated: December 15, 2015
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
2292 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 130 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Mental DisordersSchizophrenia Spectrum and Other Psychotic DisordersSchizophrenia
Criteria
3 inclusion criteria required to participate
Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria
New patients treated with Xeroquel XR
Patients aged 18 years and over
3 exclusion criteria prevent from participating
Patient included in a therapeutic trial (Huriet-Serusclat Act)
Patient refusing to participate in the study
Pregnant women
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
3 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 19 locations
Research Site
Belley, FranceResearch Site
Castelmaurou, FranceReserach Site
Cavaillon, FranceCompleted19 Study Centers